Life Science Connect Blog

  1. Does Adversity Build Character Or Reveal It? 6/12/2015

    Denice Torres is the president of McNeil Consumer Healthcare, a Johnson & Johnson company, and winner of HBA’s 2015 WOTY award. Listening to her acceptance speech reminded me of legendary pro football coach Vince Lombardi’s philosophy — “Adversity doesn’t build character, it reveals it.” 

  2. FDA Roundup: Sanofi, Genentech, Apitope, Retrophin, And More 6/11/2015

    What regulatory decisions have you missed recently?

  3. What Biopharma Trends Should Pharma Execs Be Paying Attention To? 6/11/2015

    Peter Young, a 35-year  biopharmaceutical industry veteran, presented at the 2015 BIO International, and his valuable session includes some key industry trends biopharmaceutical executives should be paying a close attention to.

  4. Will Pay-For-Performance Really Suit The Cancer Drug Space? 6/9/2015

    If Express Scripts should have its way, what would happen to inter-industry competition between the pharma players — specifically in the cancer space? If price tags are altered based off a drug’s performance, it seems to me the industry and its ways of quantifying success and leadership in the market will be faced with change as well — but it’s not entirely clear it will be what Express Scripts had in mind.

  5. FDA News Roundup: Valeant, Pfizer, Boehringer Ingelheim, And More 5/29/2015

    What FDA decisions have you missed recently?

  6. Love Me, Love Me Not — The Life Science Industry's Paradox 5/28/2015

    Cold-hearted logic dominates the quest for shareholder value, even as industry insiders complain that “nobody loves us.” What better example of the conundrum exists than the current commentary about Gilead and its wonder drugs for Hep C?

  7. Pharma's Orphan Drug Binge: Redefining Corporate Social Responsibility? 5/26/2015

    A few months ago, Senator Elizabeth Warren launched a proposal for a “swear jar” bill that would require law-breaking Big Pharma companies to contribute 1 percent of the profits from each of their blockbuster drugs to NIH research. While this proposal was highly contested by members of the industry, I questioned if there couldn’t be a benefit to this bill apart from punishing law breakers and bolstering drug R&D. Would seeing pharma push more of its profits into research boost the industry’s image?   

  8. FDA News Roundup: Baxter, Celgene, Agios, And More 5/22/2015

    What FDA decisions have you missed recently?

  9. FDA News Roundup: Vertex, Merck KGaA , Bayer, And More 5/15/2015

    What recent FDA decisions have you missed lately?

  10. Keeping Tabs On Gene Therapy? Big Pharma Is Closing In 5/12/2015

    Some good news for Big Pharma in recent weeks was GSK’s filing with the European Medicines Agency for approval of its gene therapy for ADA Severe Combined Immune Deficiency (ADA-SCID), also known as “bubble boy disease.”